Cenna Biosciences is a biopharmaceutical company dedicated to the discovery and development of novel drugs to prevent and treat Alzheimer’s disease. Cenna was founded in 2006 to translate over a decade’s academic research at the University of California San Diego (UCSD) by the inventors of the technology. The research to date has been funded by non-diluting NIH and other grants.
Alzheimer’s disease (AD) is an irreversible, progressive neurological disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. AD affects people in all parts of the world, with age being the biggest risk factor. The incidence of AD is one in ten over the age of 65, one in two by age 90.
ß-amyloid (Aß) is considered to be the major toxic species in AD. There are two major forms of Aß: Aß 40 and Aß 42. Aß accumulates in the brain in AD in plaques and coating cerebrovascular vessels. Cenna is developing novel disease-modifying drugs for Alzheimer’s disease, which inhibit the production of Aß in the brain.
5:30: Registration, Appetizers and Networking
7:45: Audience Q & A
8:00: Program Concludes, Networking, Coffee & Dessert until 8:30
REGISTRATION & COST
MITEF Members and MITEF Sponsors: Free
MIT Alums: $50
NOTE: Online Registration ends at midnight, the day prior to the event. If you register online the day of the event, you will be charged $75, the on-site price.
PAYPAL is our payment processor and accepts ALL MAJOR Credit Cards.